7614 completed, 2999 unknown, 2980 recruiting, 1990 terminated. 7526 Phase 2, 4484 Phase 1, 2783 Not applicable, 1680 Phase 3, 395 Early Phase 1.
Follow Neoplasms, Glandular and Epithelial: new trials by email Literature Review of Neoplasms, Glandular and Epithelial trials Research Report on Neoplasms, Glandular and Epithelial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial | Not applicable | Not yet recruiting | Medical College of Wisconsin | 3 | 2028-08-01 | 2026-10-13 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor | Not applicable | Enrolling by invitation | Ohio State University Comprehensive Cancer Center | 12 | 2027-10-01 | 2026-10-13 |
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Residual IDH1-Mutant Tumor Cell Quantification Study UR-ddPCR - Glioma | Not applicable | Not yet recruiting | NYU Langone Health | 105 | 2027-08-01 | 2026-09-29 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | Phase 1 | Suspended | UNC Lineberger Comprehensive Cancer Center | 6 | 2027-05-20 | 2026-04-23 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors [F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma | Early Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 28 | 2027-04-01 | 2026-08-20 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
Showing 20 of 18837. Sign in to see all of them.
Carcinoma, Hepatocellular (3372) · Glioblastoma (2068) · Carcinoma, Renal Cell (1956) · Squamous Cell Carcinoma of Head and Neck (1946) · Glioma (1448) · Carcinoma, Non-Small-Cell Lung (1195) · Neoplasms (1105) · Brain Neoplasms (941) · Head and Neck Neoplasms (897) · Breast Neoplasms (866) · Ovarian Neoplasms (863) · Carcinoma, Ovarian Epithelial (784) · Cholangiocarcinoma (778) · Carcinoma (733) · Lung Neoplasms (719)
Neoplasms by Histologic Type (18769) · Neoplasms (17732) · Neoplasms by Site (14375) · Carcinoma (13204) · Adenocarcinoma (7608) · Digestive System Diseases (5781) · Digestive System Neoplasms (5662) · Neuroectodermal Tumors (5168) · Neoplasms, Germ Cell and Embryonal (5165) · Neoplasms, Nerve Tissue (5148) · Neoplasms, Neuroepithelial (4110) · Urogenital Diseases (4061) · Urogenital Neoplasms (3927) · Female Urogenital Diseases and Pregnancy Complications (3866)
Cisplatin (1067) · Radiotherapy (832) · pembrolizumab (733) · Carboplatin (693) · Temozolomide (600) · Bevacizumab (590) · Gemcitabine (520) · Paclitaxel (512) · Nivolumab (471) · Fluorouracil (390) · Sorafenib (358) · Magnetic Resonance Spectroscopy (352) · Cyclophosphamide (343) · Docetaxel (335) · Cetuximab (273)
National Cancer Institute (NCI) (848) · Sun Yat-sen University (447) · M.D. Anderson Cancer Center (339) · Memorial Sloan Kettering Cancer Center (287) · Fudan University (180) · Mayo Clinic (152) · Novartis Pharmaceuticals (149) · Pfizer (148) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (143) · Dana-Farber Cancer Institute (117) · Children's Oncology Group (114) · University Health Network, Toronto (102) · City of Hope Medical Center (101) · Seoul National University Hospital (101) · Case Comprehensive Cancer Center (100)
United States (8647) · China (3614) · France (1582) · Canada (1250) · Italy (1150) · United Kingdom (1062) · Germany (1023) · Spain (1011) · South Korea (887) · Australia (720) · Netherlands (704) · Taiwan (686) · Belgium (603) · Japan (481) · Switzerland (406)
Ming Shi, MD (23) · Stanislaw R. Burzynski, MD, PhD (22)
PMID 37146227, PMID 31401903, PMID 40812353, PMID 37185961, PMID 30207593, PMID 31150573, PMID 33538338, PMID 12049862, PMID 25057165, PMID 27238653, PMID 28410911, PMID 29433850, PMID 11981766, PMID 19192962, PMID 20375404, PMID 12540794, PMID 18650514, PMID 19097774, PMID 25577718, PMID 36897458, PMID 37407274, PMID 19095497, PMID 22551107, PMID 23633099, PMID 25712310, PMID 29628281, PMID 29875066, PMID 32402160, PMID 33526329, PMID 34143971, PMID 34171339, PMID 36852452, PMID 38335473, PMID 12091661, PMID 16757203, PMID 19269895, PMID 21374666, PMID 27240885, PMID 27686945, PMID 27932229, PMID 28837405, PMID 29471013, PMID 29584545, PMID 32499241, PMID 32557715, PMID 32691060, PMID 32716739, PMID 33058158, PMID 33300372, PMID 34341578
2023 (133), 2018 (85), 2019 (81), 2016 (79), 2017 (72), P30CA033572 (67), U10CA032102 (65), 2025 (59), 2014 (58), 2015 (58), U10CA098543 (54), U10CA180868 (54), P30CA016672 (53), U10CA180886 (51), P30CA043703 (50)